**Executive Summary**
Union Minister Shri Jagat Prakash Nadda addressed the 11th Global Pharmaceutical Quality Summit on February 23, 2026, highlighting India's transition from "pharmacy of the world" to a "global innovation hub." This shift emphasizes healthcare security, manufacturing resilience, and scientific excellence. Government initiatives like Biopharma Shakti (₹10,000 crore outlay) and PRIP (Promotion of Research and Innovation in Pharma MedTech) are driving this transformation.
**Key Points / Main Content**
* **Transformation Focus:**
* India is transitioning from being solely a "pharmacy of the world" to a "global innovation hub."
* This transition is driven by healthcare security, manufacturing resilience, and scientific excellence.
* **Policy Framework & Initiatives:**
* India's policy framework is aligned with this transformation.
* The Biopharma Shakti initiative, with an outlay of ₹10,000 crore, will position India as a global biopharmaceutical manufacturing hub.
* PRIP (Promotion of Research and Innovation in Pharma MedTech) scheme is driving innovation in new medicines, complex generics, vaccines, and advanced medical technologies.
* **Role of Technology:**
* Emerging technologies, especially responsible AI use, are vital for strengthening predictive diagnostics, pharmaceutical traceability, pharmacovigilance, and quality systems.
* **Emphasis on Quality:**
* Quality must be embedded as a core organizational value.
* Continued investment is needed in human resources, systems, and infrastructure for a "quality-first" ecosystem.
* **Vision for India:**
* India aims to emerge as a global pharmaceutical leader, combining scale with trust, innovation with collaboration, and growth with responsibility.
**Impact Analysis**
**Pharmaceutical Industry Stakeholders**
* **Impact:**
* Expected to embrace innovation, improve quality systems, and invest in advanced technologies.
* Benefit from government initiatives like Biopharma Shakti and PRIP, leading to increased manufacturing capacity and research.
* **Action Required:**
* Embed quality as a core value.
* Invest in human resources, systems, and infrastructure.
* Leverage emerging technologies for improved diagnostics and traceability.
**Government (Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals)**
* **Impact:**
* Responsible for implementing and overseeing initiatives like Biopharma Shakti and PRIP.
* Needs to create an enabling environment for innovation and manufacturing in the pharmaceutical sector.
* **Action Required:**
* Effectively manage and deploy funds for Biopharma Shakti and PRIP.
* Ensure policy frameworks are aligned with the transformation goals.
**Indian Pharmaceutical Sector**
* **Impact**
* India is to become a global biopharmaceutical manufacturing hub, strengthening domestic production and expanding research capacity
* **Action Required**
* Continue investment in human resources, systems, and infrastructure for a sustainable “quality-first” ecosystem.
* Capitalise on PRIP (Promotion of Research and Innovation in Pharma MedTech) scheme is driving innovation in new medicines, complex generics, vaccines, and advanced medical technologies
Key Entities Referenced
Ministry of Chemicals and Fertilizers: The primary ministry overseeing the initiatives related to the pharmaceutical sector mentioned in the article.
Biopharma Shakti: A government initiative with an outlay of ₹10,000 crore aimed at positioning India as a global biopharmaceutical manufacturing hub.
PRIP (Promotion of Research and Innovation in Pharma MedTech) scheme: A scheme focused on driving innovation in the pharmaceutical and medical technology sectors.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
India is Transitioning from “Pharmacy of the
World” to a “Global Innovation Hub”- Union
Minister Shri Jagat Prakash Nadda
Posted On: 23 FEB 2026 6:11PM by PIB Delhi
Long recognized as the ‘pharmacy of the world,’ India is now transitioning into ‘innovator of the
world’ under the leadership of Hon'ble Prime Minister Narendra Mod said the Union Minister for
Chemicals and Fertilizers, Shri Jagat Prakash Nadda. Addressing the 11th Global Pharmaceutical
Quality Summit held at Mumbai through a video message today, the Minister added that this
transformation is driven by a strong focus on healthcare security, manufacturing resilience, and
scientific excellence.
Underscoring India’s growing leadership in the global pharmaceutical sector and its commitment to
quality, innovation, and healthcare security, the Minister noted that India must anchor global supply
chains not only through scale but also through quality, reliability, and innovation.
Referring to key government initiatives, Shri Nadda underlined that India’s policy framework is aligned
with this transformation. He stated that Biopharma Shakti initiative with an outlay of ₹10,000 crore, will
position India as a global biopharmaceutical manufacturing hub, strengthening domestic production,
expanding research capacity. Further, PRIP (Promotion of Research and Innovation in Pharma
MedTech) scheme is driving innovation in new medicines, complex generics, vaccines, and advanced
medical technologies, he added.
Shri Nadda also highlighted the role of emerging technologies, particularly responsible use of artificial
intelligence, in strengthening predictive diagnostics, pharmaceutical traceability, pharmacovigilance, and
overall quality systems. Calling upon industry stakeholders, he stressed that quality must be embedded as
a core organizational value rather than treated merely as a compliance requirement. He emphasized the
need for continued investment in human resources, systems, and infrastructure to build a sustainable
“quality-first” ecosystem.The Minister reiterated India’s vision to emerge as a global pharmaceutical leader that combines scale
with trust, innovation with collaboration, and growth with responsibility, thereby contributing significantly
to global healthcare outcomes.
****
PC/PM
(Release ID: 2231846) Visitor Counter : 368
Read this release in: Marathi , Urdu , ही